Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.
J Immunother Cancer. 2022 Sep;10(9):e004450. doi: 10.1136/jitc-2021-004450.
J Immunother Cancer. 2022.
PMID: 36167467
Free PMC article.
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.
Heitzeneder S, Bosse KR, Zhu Z, Zhelev D, Majzner RG, Radosevich MT, Dhingra S, Sotillo E, Buongervino S, Pascual-Pasto G, Garrigan E, Xu P, Huang J, Salzer B, Delaidelli A, Raman S, Cui H, Martinez B, Bornheimer SJ, Sahaf B, Alag A, Fetahu IS, Hasselblatt M, Parker KR, Anbunathan H, Hwang J, Huang M, Sakamoto K, Lacayo NJ, Klysz DD, Theruvath J, Vilches-Moure JG, Satpathy AT, Chang HY, Lehner M, Taschner-Mandl S, Julien JP, Sorensen PH, Dimitrov DS, Maris JM, Mackall CL.
Heitzeneder S, et al.
Cancer Cell. 2022 Jan 10;40(1):53-69.e9. doi: 10.1016/j.ccell.2021.12.005. Epub 2021 Dec 30.
Cancer Cell. 2022.
PMID: 34971569
Free PMC article.
Item in Clipboard
Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization.
Buongervino S, Lane MV, Garrigan E, Zhelev DV, Dimitrov DS, Bosse KR.
Buongervino S, et al.
Mol Cancer Ther. 2021 Nov;20(11):2228-2239. doi: 10.1158/1535-7163.MCT-20-1034. Epub 2021 Aug 31.
Mol Cancer Ther. 2021.
PMID: 34465595
Free PMC article.
Item in Clipboard
A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope.
Raman S, Buongervino SN, Lane MV, Zhelev DV, Zhu Z, Cui H, Martinez B, Martinez D, Wang Y, Upton K, Patel K, Rathi KS, Navia CT, Harmon DB, Li Y, Pawel B, Dimitrov DS, Maris JM, Julien JP, Bosse KR.
Raman S, et al. Among authors: buongervino sn.
Cell Rep Med. 2021 Jul 21;2(7):100344. doi: 10.1016/j.xcrm.2021.100344. eCollection 2021 Jul 20.
Cell Rep Med. 2021.
PMID: 34337560
Free PMC article.
Item in Clipboard
Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma.
Bosse KR, Giudice AM, Lane MV, McIntyre B, Schürch PM, Pascual-Pasto G, Buongervino SN, Suresh S, Fitzsimmons A, Hyman A, Gemino-Borromeo M, Saggio J, Berko ER, Daniels AA, Stundon J, Friedrichsen M, Liu X, Margolis ML, Li MM, Tierno MB, Oxnard GR, Maris JM, Mossé YP.
Bosse KR, et al. Among authors: buongervino sn.
Cancer Discov. 2022 Dec 2;12(12):2800-2819. doi: 10.1158/2159-8290.CD-22-0287.
Cancer Discov. 2022.
PMID: 36108156
Free PMC article.
Item in Clipboard
GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies.
Pascual-Pasto G, McIntyre B, Shraim R, Buongervino SN, Erbe AK, Zhelev DV, Sadirova S, Giudice AM, Martinez D, Garcia-Gerique L, Dimitrov DS, Sondel PM, Bosse KR.
Pascual-Pasto G, et al. Among authors: buongervino sn.
J Immunother Cancer. 2022 Dec;10(12):e004704. doi: 10.1136/jitc-2022-004704.
J Immunother Cancer. 2022.
PMID: 36460335
Free PMC article.
Item in Clipboard
Cite
Cite